



Paris, June 23th 2015

Kurma Partners expands its investment team with the appointment of Alain Horvais and Philippe Peltier as Partners and announces the promotion of Vanessa Malier as Managing Partner.

Paris, June 23th 2015. **Alain Horvais** and **Philippe Peltier** join Kurma Partners to serve as Partners in charge of the management of Kurma Diagnostics funds launched on May 26, 2015.

Alain Horvais (51) brings to Kurma Partners more than 20 years of experience in the *in vitro* diagnostic industry and entrepreneurship. Further to the co-foundation of his diagnostic company in 1995 (D-Genos), he served as R&D Director at Bio-Rad in 2001 and was in charge of PCR based products. Prior to joining Kurma Partners, he served as Director Companion Diagnostic at Astra Zeneca in the UK.

Philippe Peltier (44) has over 15 years of investing experience in venture capital in the life science industry. Before joining Kurma Partners, Philippe was a Partner at Auriga Partners since 1999. He has invested and served on the board of more than 15 investments in France and abroad.

Alain and Philippe are strengthening the know-how of Kurma Partners by combining operational experience in *in vitro* diagnostic and savoir faire in venture capital investment. This complementary know-how will be put at work in the management of Kurma Diagnostic fund. The two new partners are joined by Simon Turner as an analyst. Simon graduated from King's College in London and from SKEM Business School. Simon was previously a consultant in life sciences and joined Kurma Partners in January 2014.

Vanessa Malier, Partner since September 2013 is promoted to Managing Partner. She joins Thierry Laugel (Chairman) and Remi Droller on the executive board of the firm to manage and develop its business.

About Kurma Partners

Founded in July 2009, Kurma Partners is a key European player in venture capital, development capital and technology transfer in the field of life sciences (biotechnology, pharmaceuticals, medical devices and diagnostic platforms), notably through Kurma Biofund I, Kurma Biofund II, and strategic partnerships with forefront European biotechnology medical research centres.

Contacts :

Alain Horvais	alain.horvais@kurmapartners.com
Philippe Peltier	philippe.peltier@kurmapartners.com
Vanessa Malier	vm@kurmapartners.com